Clinical Trials Logo

Recurrent Neuroendocrine Tumor clinical trials

View clinical trials related to Recurrent Neuroendocrine Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT03034200 Recruiting - Clinical trials for Recurrent Neuroendocrine Tumor

Phase 2 Study of ONC201 in Neuroendocrine Tumors

Start date: August 1, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to learn if a new drug, ONC201 can make tumors become smaller or go away completely. Investigators also want to learn if ONC201 can prevent new deposits of cancer from appearing in new places in participants (metastases). A phase 2 study of ONC201 in PC-PG (pheochromocytoma-paraganglioma) and other neuroendocrine tumors will determine whether inhibition of DRD2 (a member of the dopamine receptor family) is safe in neuroendocrine cancers including PC-PG. ONC201 is an investigational (experimental) agent and has a favorable safety profile in phase 1 and early phase 2 clinical trials in advanced cancers. This study design has been chosen to see whether ONC201 is associated with reduction of anti-hypertension medications, safety and significant efficacy against neuroendocrine tumors, especially PC-PG.